Major Distribution Agreement for Asia for ELIXIA Products
Filed with ASX ·
6ix hasn’t read this filing yet.
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- Successful $24.1m Capital Raising and $3m SPP
- POH Signs License Agreement with Intas Pharmaceuticals
- POH Further Refinements to Oxycodone Patch Design
- POH adds David Jones as retail partner for Elixia products
- Pivotal TPM-oxycodone Patch Trials Begin
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology